Ceritinib
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Anaplastic Thyroid Cancer
Conditions
Metastatic Anaplastic Thyroid Cancer, Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer
Trial Timeline
Jun 1, 2015 → Jan 1, 2019
NCT ID
NCT02289144About Ceritinib
Ceritinib is a phase 2 stage product being developed by Novartis for Metastatic Anaplastic Thyroid Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02289144. Target conditions include Metastatic Anaplastic Thyroid Cancer, Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Anaplastic Thyroid Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05100134 | Pre-clinical | Active |
| NCT02584933 | Approved | Active |
| NCT02638909 | Phase 2 | Terminated |
| NCT02513667 | Phase 2 | Terminated |
| NCT02289144 | Phase 2 | Withdrawn |
| NCT02343679 | Phase 2 | Withdrawn |
| NCT02299505 | Phase 1 | Completed |
| NCT02336451 | Phase 2 | Completed |
| NCT02186821 | Phase 2 | Terminated |
| NCT01742286 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Anaplastic Thyroid Cancer